HUE049769T2 - Humán komplemens C2 faktort kötõ kötõ molekulák és alkalmazásaik - Google Patents

Humán komplemens C2 faktort kötõ kötõ molekulák és alkalmazásaik

Info

Publication number
HUE049769T2
HUE049769T2 HUE14729463A HUE14729463A HUE049769T2 HU E049769 T2 HUE049769 T2 HU E049769T2 HU E14729463 A HUE14729463 A HU E14729463A HU E14729463 A HUE14729463 A HU E14729463A HU E049769 T2 HUE049769 T2 HU E049769T2
Authority
HU
Hungary
Prior art keywords
binding molecules
complement factor
human complement
bind human
bind
Prior art date
Application number
HUE14729463A
Other languages
English (en)
Hungarian (hu)
Inventor
Cornelis Erik Hack
Cafer Yildiz
Louis Boon
Petrus Johannes Simons
Original Assignee
Broteio Pharma B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broteio Pharma B V filed Critical Broteio Pharma B V
Publication of HUE049769T2 publication Critical patent/HUE049769T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HUE14729463A 2013-05-23 2014-05-22 Humán komplemens C2 faktort kötõ kötõ molekulák és alkalmazásaik HUE049769T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13168941 2013-05-23

Publications (1)

Publication Number Publication Date
HUE049769T2 true HUE049769T2 (hu) 2020-10-28

Family

ID=48485015

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE14729463A HUE049769T2 (hu) 2013-05-23 2014-05-22 Humán komplemens C2 faktort kötõ kötõ molekulák és alkalmazásaik
HUE20165165A HUE057858T2 (hu) 2013-05-23 2014-05-22 Humán komplement faktor C2B-t megkötõ kötõ molekulák és alkalmazásaik

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE20165165A HUE057858T2 (hu) 2013-05-23 2014-05-22 Humán komplement faktor C2B-t megkötõ kötõ molekulák és alkalmazásaik

Country Status (14)

Country Link
US (2) US9944717B2 (enExample)
EP (2) EP2999714B1 (enExample)
JP (3) JP2016520313A (enExample)
CN (1) CN105492461B (enExample)
AU (1) AU2014269193C1 (enExample)
CA (1) CA2913318C (enExample)
DK (2) DK3725803T3 (enExample)
ES (2) ES2904709T3 (enExample)
HU (2) HUE049769T2 (enExample)
LT (2) LT3725803T (enExample)
MX (1) MX366046B (enExample)
PL (2) PL2999714T3 (enExample)
PT (2) PT3725803T (enExample)
WO (1) WO2014189378A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6543572B2 (ja) 2012-11-02 2019-07-10 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
CA2913318C (en) * 2013-05-23 2024-03-26 Broteio Pharma B.V. Binding molecules that bind human complement factor c2 and uses thereof
HRP20251304T1 (hr) 2016-10-12 2025-12-05 Bioverativ Usa Inc. Anti-c1s protutijela i postupci njihove upotrebe
SG11202105195PA (en) * 2018-12-13 2021-06-29 Argenx Bvba Antibodies to human complement factor c2b and methods of use
GB2584105B (en) 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
US20220332804A1 (en) * 2019-08-12 2022-10-20 Csl Innovation Pty Ltd. Complement C2 Binding Proteins and Uses Thereof
AU2023210793A1 (en) * 2022-01-29 2024-06-06 Kira Pharmaceuticals (Suzhou) Ltd. Anti-c2 antibodies and uses thereof
GB202407051D0 (en) 2024-05-17 2024-07-03 argenx BV Methods of treating osteoarthritis pain
WO2025257157A1 (en) 2024-06-10 2025-12-18 argenx BV Treatment or prevention of ischemia reperfusion injury in organ tranplantation
WO2025260123A1 (en) * 2024-06-17 2025-12-26 CSL Innovation Pty Ltd Anti-c2 antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO2001070818A1 (en) * 2000-03-23 2001-09-27 Tanox, Inc. Anti-c2/c2a inhibitors of complement activation
CA2913318C (en) 2013-05-23 2024-03-26 Broteio Pharma B.V. Binding molecules that bind human complement factor c2 and uses thereof

Also Published As

Publication number Publication date
JP7163254B2 (ja) 2022-10-31
LT2999714T (lt) 2020-07-10
PL3725803T3 (pl) 2022-04-04
US10717785B2 (en) 2020-07-21
EP3725803B1 (en) 2021-12-15
JP7414929B2 (ja) 2024-01-16
HUE057858T2 (hu) 2022-06-28
PT3725803T (pt) 2021-12-24
JP2023002684A (ja) 2023-01-10
US20180319895A1 (en) 2018-11-08
US9944717B2 (en) 2018-04-17
PT2999714T (pt) 2020-04-30
CA2913318A1 (en) 2014-11-27
CN105492461B (zh) 2019-11-26
ES2904709T3 (es) 2022-04-05
EP2999714B1 (en) 2020-04-01
EP3725803A1 (en) 2020-10-21
CA2913318C (en) 2024-03-26
WO2014189378A1 (en) 2014-11-27
HK1223385A1 (zh) 2017-07-28
CN105492461A (zh) 2016-04-13
PL2999714T3 (pl) 2020-10-19
ES2784616T3 (es) 2020-09-29
DK2999714T3 (da) 2020-06-02
US20160108134A1 (en) 2016-04-21
EP2999714A1 (en) 2016-03-30
JP2016520313A (ja) 2016-07-14
DK3725803T3 (da) 2022-03-07
MX366046B (es) 2019-06-26
LT3725803T (lt) 2022-03-10
JP2020007318A (ja) 2020-01-16
AU2014269193B2 (en) 2019-08-15
MX2015016120A (es) 2016-10-28
AU2014269193C1 (en) 2020-02-20
AU2014269193A1 (en) 2015-12-17

Similar Documents

Publication Publication Date Title
ZA201505209B (en) Binding molecules for bcma and cd3
IL254223A (en) CD20 binding compounds and their uses
IL240045A0 (en) Antigen-binding molecules activate bi-specific t cells
IL240838A0 (en) Anti-3–lag binding proteins
HUE049769T2 (hu) Humán komplemens C2 faktort kötõ kötõ molekulák és alkalmazásaik
SG11201505762XA (en) Il-11r binding proteins and uses thereof
SG11201600275PA (en) Novel adsorbent composition and use thereof
ZA201506186B (en) Ligand binding molecules and uses thereof
LT3077467T (lt) Džioviklio kompozicija ir jos panaudojimas
SI3072905T1 (sl) IL-17A-vezavno sredstvo in uporabe le-tega
ZA201507808B (en) Binding element
GB201306588D0 (en) Peptides and Binding Partners Therefor
ZA201503962B (en) Fines binding process and binding composition thereof
HU4488U (en) Plaster-coated and edge-protected chipboard
GB201314294D0 (en) Binding surfaces